Plasma-derived nanoparticles
AssigneeNanomedx, Inc.
InventorsMiguel Angelo Correia Dos Santos, Elysse Filipe, Praveesuda Lorwattanapongsa, Marcela Bilek, Steven Garry Wise
Life of this patent
Estimating the term…
Abstract
This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.
Claims15
A conjugate comprising:
- an aggregate comprising two or more nanoparticulate polymers having mean diameters of 1 nm to 50 nm, wherein the aggregate has a mean diameter of 5 nm to 500 nm, and wherein the nanoparticulate polymers are formed from a plasma comprising acetylene;
- and
- at least one compound selected from the group consisting of:
- a targeting ligand, an amino acid, a peptide, a synthetic analogue of a natural bioactive molecule, a synthetic peptide mimetic, a protein, a receptor-targeting ligand, a gene targeting agent, a polynucleotide, and an RNA.
A pharmaceutical composition comprising:
- an aggregate comprising two or more nanoparticulate polymers having mean diameters of 1 nm to 50 nm, wherein the aggregate has a mean diameter of 5 nm to 500 nm, and wherein the nanoparticulate polymers are formed from a plasma comprising acetylene;
- and
- at least one compound selected from the group consisting of:
- a targeting ligand, an amino acid, a peptide, a synthetic analogue of a natural bioactive molecule, a synthetic peptide mimetic, a protein, a receptor-targeting ligand, a gene targeting agent, a polynucleotide, and an RNA;
- and a pharmaceutically acceptable carrier, excipient, or binder.
A method of treating a subject suffering from, susceptible to, or displaying one or more symptoms of a disease, disorder, or condition, the method comprising a step of administering:
- i) a conjugate comprising:
- an aggregate comprising two or more nanoparticulate polymers having mean diameters of 1 nm to 50 nm, wherein the aggregate has a mean diameter of 5 nm to 500 nm and wherein the nanoparticulate polymers are formed from a plasma comprising acetylene;
- and
- at least one compound selected from the group consisting of:
- a targeting ligand, an amino acid, a peptide, a synthetic analogue of a natural bioactive molecule, a synthetic peptide mimetic, a protein, a receptor-targeting ligand, a gene targeting agent, a polynucleotide, and an RNA, or
- ii) a pharmaceutical composition comprising the conjugate of i) and a pharmaceutically acceptable carrier, excipient, or binder,
- to the subject, wherein the disease, disorder, or condition is selected from the group consisting of:
- acute coronary syndrome, an aging-related disease or disorder, an allergic disease or a related condition, Alzheimer's disease, asthma, HIV, antibiotic resistance, atherosclerosis, an autoimmune disease, a bacterial infection, cancer, dementia, depression or a related condition, diabetes, dyslipidemia, hyperlipidemia, hypertension, ichthyosis, an immune disease, a metabolic disease or disorder, a neurological disease or disorder, obesity, Parkinson's disease, pain, rheumatoid arthritis, and a proliferative disease.
Dependencies are inferred from the claim text.